These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
93 related articles for article (PubMed ID: 28977949)
1. Is FOLFOXIRI alone or combined with targeted therapy administered as first-line treatment a reasonable choice for most patients with mCRC? Systematic review and network meta-analysis. Zhou M; Yu P; Hernick Davin DB; Li Y; Wang Y; Fu L; Zhang J Oncotarget; 2017 Sep; 8(37):62339-62348. PubMed ID: 28977949 [TBL] [Abstract][Full Text] [Related]
2. Phase II Randomized Trial of Sequential or Concurrent FOLFOXIRI-Bevacizumab Versus FOLFOX-Bevacizumab for Metastatic Colorectal Cancer (STEAM). Hurwitz HI; Tan BR; Reeves JA; Xiong H; Somer B; Lenz HJ; Hochster HS; Scappaticci F; Palma JF; Price R; Lee JJ; Nicholas A; Sommer N; Bendell J Oncologist; 2019 Jul; 24(7):921-932. PubMed ID: 30552157 [TBL] [Abstract][Full Text] [Related]
3. Triplet Chemotherapy (FOLFOXIRI) Plus Bevacizumab Versus Doublet Chemotherapy (FOLFOX/FOLFIRI) Plus Bevacizumab in Conversion Therapy for Metastatic Colorectal Cancer: a Meta-Analysis. Shui L; Wu YS; Lin H; Shui P; Sun Q; Chen X Cell Physiol Biochem; 2018; 48(5):1870-1881. PubMed ID: 30092572 [TBL] [Abstract][Full Text] [Related]
4. FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer. Loupakis F; Cremolini C; Salvatore L; Masi G; Sensi E; Schirripa M; Michelucci A; Pfanner E; Brunetti I; Lupi C; Antoniotti C; Bergamo F; Lonardi S; Zagonel V; Simi P; Fontanini G; Falcone A Eur J Cancer; 2014 Jan; 50(1):57-63. PubMed ID: 24138831 [TBL] [Abstract][Full Text] [Related]
5. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. Falcone A; Ricci S; Brunetti I; Pfanner E; Allegrini G; Barbara C; Crinò L; Benedetti G; Evangelista W; Fanchini L; Cortesi E; Picone V; Vitello S; Chiara S; Granetto C; Porcile G; Fioretto L; Orlandini C; Andreuccetti M; Masi G; J Clin Oncol; 2007 May; 25(13):1670-6. PubMed ID: 17470860 [TBL] [Abstract][Full Text] [Related]
6. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Cremolini C; Loupakis F; Antoniotti C; Lupi C; Sensi E; Lonardi S; Mezi S; Tomasello G; Ronzoni M; Zaniboni A; Tonini G; Carlomagno C; Allegrini G; Chiara S; D'Amico M; Granetto C; Cazzaniga M; Boni L; Fontanini G; Falcone A Lancet Oncol; 2015 Oct; 16(13):1306-15. PubMed ID: 26338525 [TBL] [Abstract][Full Text] [Related]
7. FOLFIRI plus cetuximab in patients with liver-limited or non-liver-limited RAS wild-type metastatic colorectal cancer: A retrospective subgroup analysis of the CRYSTAL study. Köhne CH; Poston G; Folprecht G; Ciardiello F; Ronga P; Beier F; Van Cutsem E Eur J Surg Oncol; 2016 Oct; 42(10):1540-7. PubMed ID: 27575968 [TBL] [Abstract][Full Text] [Related]
8. Survival benefit and safety of the combinations of FOLFOXIRI ± bevacizumab versus the combinations of FOLFIRI ± bevacizumab as first-line treatment for unresectable metastatic colorectal cancer: a meta-analysis. Xu W; Kuang M; Gong Y; Cao C; Chen J; Tang C Onco Targets Ther; 2016; 9():4833-42. PubMed ID: 27536147 [TBL] [Abstract][Full Text] [Related]
9. Who will benefit more from maintenance therapy of metastatic colorectal cancer? Zhou M; Fu L; Zhang J Oncotarget; 2018 Feb; 9(15):12479-12486. PubMed ID: 29552327 [TBL] [Abstract][Full Text] [Related]
11. Doublet chemotherapy vs. single-agent therapy with 5FU in elderly patients with metastatic colorectal cancer. a meta-analysis. Landre T; Uzzan B; Nicolas P; Aparicio T; Zelek L; Mary F; Taleb C; Des Guetz G Int J Colorectal Dis; 2015 Oct; 30(10):1305-10. PubMed ID: 26099322 [TBL] [Abstract][Full Text] [Related]
12. Primary tumor sidedness and benefit from FOLFOXIRI plus bevacizumab as initial therapy for metastatic colorectal cancer. Retrospective analysis of the TRIBE trial by GONO. Cremolini C; Antoniotti C; Lonardi S; Bergamo F; Cortesi E; Tomasello G; Moretto R; Ronzoni M; Racca P; Loupakis F; Zaniboni A; Tonini G; Buonadonna A; Marmorino F; Allegrini G; Granetto C; Masi G; Zagonel V; Sensi E; Fontanini G; Boni L; Falcone A Ann Oncol; 2018 Jul; 29(7):1528-1534. PubMed ID: 29873679 [TBL] [Abstract][Full Text] [Related]
13. Individual Patient Data Meta-Analysis of FOLFOXIRI Plus Bevacizumab Versus Doublets Plus Bevacizumab as Initial Therapy of Unresectable Metastatic Colorectal Cancer. Cremolini C; Antoniotti C; Stein A; Bendell J; Gruenberger T; Rossini D; Masi G; Ongaro E; Hurwitz H; Falcone A; Schmoll HJ; Di Maio M J Clin Oncol; 2020 Aug; ():JCO2001225. PubMed ID: 32816630 [TBL] [Abstract][Full Text] [Related]
14. Outcome of second-line treatment after first-line chemotherapy with the GONO FOLFOXIRI regimen. Fornaro L; Vasile E; Masi G; Loupakis F; Baldi GG; Allegrini G; Salvatore L; Cremolini C; Cupini S; Cortesi E; Tuzi A; Granetto C; Brunetti IM; Ricci S; Falcone A Clin Colorectal Cancer; 2012 Mar; 11(1):71-6. PubMed ID: 21903485 [TBL] [Abstract][Full Text] [Related]
15. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. Peeters M; Price TJ; Cervantes A; Sobrero AF; Ducreux M; Hotko Y; André T; Chan E; Lordick F; Punt CJ; Strickland AH; Wilson G; Ciuleanu TE; Roman L; Van Cutsem E; Tzekova V; Collins S; Oliner KS; Rong A; Gansert J J Clin Oncol; 2010 Nov; 28(31):4706-13. PubMed ID: 20921462 [TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of Systemic Treatments Among Colorectal Cancer Patients: A Network Meta-Analysis of Randomized Controlled Trials. Hoang T; Sohn DK; Kim BC; Cha Y; Kim J Front Oncol; 2021; 11():756214. PubMed ID: 35223449 [TBL] [Abstract][Full Text] [Related]
17. Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial. Masi G; Loupakis F; Salvatore L; Fornaro L; Cremolini C; Cupini S; Ciarlo A; Del Monte F; Cortesi E; Amoroso D; Granetto C; Fontanini G; Sensi E; Lupi C; Andreuccetti M; Falcone A Lancet Oncol; 2010 Sep; 11(9):845-52. PubMed ID: 20702138 [TBL] [Abstract][Full Text] [Related]
18. Single Nucleotide Polymorphisms in MiRNA Binding Sites of Nucleotide Excision Repair-Related Genes Predict Clinical Benefit of Oxaliplatin in FOLFOXIRI Plus Bevacizumab: Analysis of the TRIBE Trial. Suenaga M; Schirripa M; Cao S; Zhang W; Yang D; Cremolini C; Murgioni S; Lonardi S; Ning Y; Okazaki S; Berger MD; Miyamoto Y; Barzi A; Loupakis F; Falcone A; Lenz HJ Cancers (Basel); 2020 Jun; 12(7):. PubMed ID: 32629861 [TBL] [Abstract][Full Text] [Related]
19. A phase II trial of 1st-line modified-FOLFOXIRI plus bevacizumab treatment for metastatic colorectal cancer harboring RAS mutation: JACCRO CC-11. Satake H; Sunakawa Y; Miyamoto Y; Nakamura M; Nakayama H; Shiozawa M; Makiyama A; Kobayashi K; Kubota Y; Mori M; Kotaka M; Takagane A; Gotoh M; Takeuchi M; Fujii M; Ichikawa W; Sekikawa T Oncotarget; 2018 Apr; 9(27):18811-18820. PubMed ID: 29721163 [TBL] [Abstract][Full Text] [Related]
20. Network meta-analysis of the efficacy of first-line chemotherapy regimens in patients with advanced colorectal cancer. Wu DM; Wang YJ; Fan SH; Zhuang J; Zhang ZF; Shan Q; Han XR; Wen X; Li MQ; Hu B; Sun CH; Bao YX; Xiao HJ; Yang L; Lu J; Zheng YL Oncotarget; 2017 Nov; 8(59):100668-100677. PubMed ID: 29246011 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]